Atbin D. T.
- Country
- Austria
- Department
- NA
Research Overview
- Oral semaglutide versus placebo in early Alzheimer’s disease: a randomized double-blind trial in patients with mild cognitive impairment or mild dementia
- Efficacy and Safety Evaluation of BIIB122 in a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study in Parkinson's Disease Patients
- Evaluation of Tominersen Safety, Biomarkers, and Efficacy in Prodromal and Early Manifest Huntington's Disease: A Phase II Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 153 of 246 partner sites.
Specializations
Neurodegenerative Disorders
This investigator specializes in researching advanced therapeutic approaches for neurodegenerative conditions, with a particular focus on early-stage interventions.
- Early Alzheimer's Disease Management
- Cognitive Impairment Assessment
- Dementia Care Innovation
The investigator explores novel therapeutic strategies for managing cognitive decline and preserving mental function in early-stage neurological conditions.
Movement Disorders
The investigator has developed expertise in Parkinson's Disease treatment, particularly focusing on early-stage interventions and innovative therapeutic approaches.
- Early Parkinson's Disease Treatment
- Motor Function Assessment
- Disease Progression Management
Their research encompasses comprehensive evaluation of motor function and disease progression in movement disorders.
Clinical Assessment Methods
The investigator utilizes specialized clinical rating scales and assessment tools to evaluate treatment efficacy in neurological conditions.
- Clinical Dementia Rating Assessment
- Movement Disorder Society Rating Scales
- Standard of Care Integration
Their work involves implementing standardized evaluation methods to measure therapeutic outcomes in neurological disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.